Furthermore, this review explores the potential of targeting NEU1 as a therapeutic strategy to modulate EV glycosylation and mitigate the progression of AD, thereby addressing the urgent need for novel interventions in this debilitating disease [59]. This evidence concerns the gene NEU1 and Alzheimer disease.